The efficacy and safety of hepatic arterial infusion of oxaliplatin plus intravenous irinotecan, leucovorin and fluorouracil in colorectal cancer with inoperable hepatic metastasis

References

• Ferlay J, Shin H, Bray F, Forman D, Mathers C, Maxwell Parkin D. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2005;127:2893–917.
   Web of Science ®Google Scholar
• Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006;244:254–9.
   PubMed Web of Science ®Google Scholar
• Penna C, Nordingler B. Colorectal metastasis (liver and lung). Surg Clin North Am. 2002;82:1075–1090; x–xi.
   PubMed Web of Science ®Google Scholar
• Thirion P, Michiels S, Pignon JP, Buyse M, Braud AC, Carlson RW. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol. 2004;22:3766–3775.
   PubMed Web of Science ®Google Scholar
• Grothey A, Schmoll HJ. New chemotherapy approaches in colorectal cancer. Curr Opin Oncol. 2001;13:275–286.
   PubMed Web of Science ®Google Scholar
• Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR. Oxaliplatin, fluorouracil and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group Phase II Study. J Clin Oncol. 2005;23:9243.
   PubMed Web of Science ®Google Scholar
• Barone C, Nuzzo G, Cassano A, Basso M, Schinzari G, Giuliante F. Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases. Br J Cancer. 2007;97:1035–9.
   PubMed Web of Science ®Google Scholar
• Breedis C, Young C. The blood supply of neoplasm in the liver. Am J Pathol. 1954;30:969–974.
   PubMed Web of Science ®Google Scholar
• Chen Y, Yan Z, Wang J, Wang X, Luo J, Liu Q. Hepatic arterial infusion with oxaliplatin, irinotecan and doxifluridine for unresectable liver metastases of colorectal cancer. Anticancer Res. 2010;30:3045–3050.
   PubMed Web of Science ®Google Scholar
• Benson A. Therapy for advanced colorectal cancer. Semin Oncol. 1998;25(Suppl 11):2–11.
   PubMedGoogle Scholar
• Shitara K, Munakata M, Kudo T, Kasai M, Muto O, Okada R. Combination chemotherapy with hepatic arterial infusion of 5-fluorouracil (5-FU) and systemic irinotecan (CPT-11) in patients with resectable liver metastases from colorectal cancer. Gan To Kagaku Ryoho. 2006;33:2033–2037.
   PubMedGoogle Scholar
• Gallagher DJ, Capanu M, Raggio G, Kemeny N. Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: a retrospective analysis. Ann Oncol. 2007;18:1995–199.
   PubMed Web of Science ®Google Scholar
• Tsimberidou A, Fu S, Ng C, Lim JA, Wen S, Hong D. A Phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver. Cancer. 2010;116:4086–4094.
   PubMed Web of Science ®Google Scholar
• Tsuchiya M, Watanabe M, Koike J, Kubota Y, Suzuki T, Otsuka Y. Hepatic arterial infusion chemotherapy with oxaliplatin in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Gan To Kagaku Ryoho. 2010;37(12):2594–2597.
   PubMedGoogle Scholar
• Melichar B, Ferko A, Krajina A, Rousková L, Dvorák J, Svébisova H. Hepatic arterial infusion of oxaliplatin, 5-fluorouracil and leucovorin in patients with liver metastases from colorectal carcinoma. J BUON. 2012;17:677–683.
   PubMed Web of Science ®Google Scholar
• Ducreux M, Ychou M, Laplanche A, Gamelin E, Lasser P, Husseini F, et al. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the Gastrointestinal Group of the FédérationNationale des Centres de LutteContre le Cancer. J Clin Oncol. 2005;23:4881–4887.
   PubMed Web of Science ®Google Scholar
• Masi G, Cupini S, Marcucci L, Cerri E, Loupakis F, Allegrini G. Treatment with 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. Ann Surg Oncol. 2006;13:58–65.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse J, Bogaerts LH, Schwartz D, Sargent R, Ford J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–247.
   PubMed Web of Science ®Google Scholar
• Simon R. Optimal two-stage designs for Phase II clinical trials. Control Clin Trials. 1989;10:1–10.
   PubMedGoogle Scholar
• Jung SH, Lee TY, Kim KM, George S. Admissible two-stage designs for Phase II cancer clinical trials. Stat Med. 2004;23:561–9.
   PubMed Web of Science ®Google Scholar
• Falcone A, Masi G, Allegrini G, Danesi R, Pfanner E, Brunetti IM. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol. 2002;20:4006–14.
   PubMed Web of Science ®Google Scholar
• Masi G, Allegrini G, Cupini S, Marcucci L, Cerri E, Brunetti I. First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a Phase II study with a simplified biweekly schedule. Ann Oncol. 2004;15:1766–72.
   PubMed Web of Science ®Google Scholar
• Fischel JL, Rostagno P, Formento P, Dubreuil A, Etienne MC, Milano G. Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines. Br J Cancer. 2001;84:579–585.
   PubMed Web of Science ®Google Scholar
• Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23–30.
   PubMed Web of Science ®Google Scholar
• Souglakos J, Androulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs. FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer. 2006;94:798–805.
   PubMed Web of Science ®Google Scholar
• Goetz MP, Erlichman C, Windebank AJ, Reid JM, Sloan JA, Atherton P. Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, fluorouracil, and leucovorin in patients with solid tumors. J Clin Oncol. 2003;21:3761–3769.
   PubMed Web of Science ®Google Scholar
• Hoff PM, Wolff RA, Xiong H, Jones D, Lin E, Eng C. Phase II trial of combined irinotecan and oxaliplatin given every 3 weeks to patients with metastatic colorectal cancer. Cancer. 2006;15:2241–2246.
   Web of Science ®Google Scholar
• Sanoff HK, Sargent DJ, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol. 2006;26:5721–5727.
   Web of Science ®Google Scholar
• Masi G, Vasile E, Loupakis F, Cupini S, Fornaro L, Baldi G. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. J Natl Cancer Inst. 2011;103:21–30.
   PubMed Web of Science ®Google Scholar
• Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the GruppoOncologico Nord Ovest. J Clin Oncol. 2007;25:1670–6.
   PubMed Web of Science ®Google Scholar
• Rougier P, Ducreux M, Pignon JP, Elias D, Tigaud JM, Lumbroso J. Prognostic factors in patients with liver metastases from colorectal carcinoma treated with discontinuous intra-arterial hepatic chemotherapy. Eur J Cancer. 1991;27:1226–30.
   PubMed Web of Science ®Google Scholar
• Safi F, Bittner R, Roscher R, Schuhmacher K, Gaus W, Beger GH. Regional chemotherapy for hepatic metastases of colorectal carcinoma (continuous intra-arterial versus continuous intra-arterial/intravenous therapy). Results of a controlled clinical trial. Cancer. 1998;64:379–387.
   Web of Science ®Google Scholar